Positive results from pivotal trials of exa-cel for transfusion-dependent beta thalassemia and severe sickle cell disease presented at the 2023 annual european hematology association (eha) congress

Boston & zug, switzerland--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) and crispr therapeutics (nasdaq: crsp) today announced that both pivotal trials for exagamglogene autotemcel (exa-cel) in patients with transfusion-dependent beta thalassemia (tdt) or severe sickle cell disease (scd) met primary and key secondary endpoints at pre-specified interim analyses. the results are being presented at the annual european hematology association (eha) congress. “the updated resul.
VRTX Ratings Summary
VRTX Quant Ranking